FDA Lifts Partial Clinical Hold on Trials for OncoMed’s Vantictumab

Drug Industry Daily
Cancer drugmaker OncoMed expects to resume enrollment and dosing of new patients for its experimental oncology drug vantictumab within the next few weeks, after the FDA removed a partial clinical hold on its clinical trials.

To View This Article:


Subscribe To Drug Industry Daily